First-line ribociclib and endocrine therapy may be more effective than combined chemotherapy in aggressive breast cancer

by American Association for Cancer ResearchCredit: Pixabay/CC0 Public DomainIn patients with hormone receptor-positive, HER2-negative, advanced breast cancer—including patients with visceral cris

Oncology February 01,2024

First-line ribociclib and endocrine therapy may be more effective than combined chemotherapy in aggressive breast cancer

by American Association for Cancer ResearchCredit: Pixabay/CC0 Public DomainIn patients with hormone receptor-positive, HER2-negative, advanced breast cancer—including patients with visceral cris

Oncology February 01,2024

An elusive mechanism of wasting syndrome cachexia revealed

by Justin Jackson , Medical XpressOSM induces Eda2r expression in muscle and the depletion of OSMR protects from muscle wasting. a, Mouse primary myotubes were treated with recombinant TNFα, IL-6, LIF

Oncology February 01,2024

An elusive mechanism of wasting syndrome cachexia revealed

by Justin Jackson , Medical XpressOSM induces Eda2r expression in muscle and the depletion of OSMR protects from muscle wasting. a, Mouse primary myotubes were treated with recombinant TNFα, IL-6, LIF

Oncology February 01,2024

Study: Tumor necroptosis promotes metastasis by modulating tumor-host immunity

by Impact Journals LLCTumor necroptosis promotes metastasis of breast cancer by suppressing anti-tumor immunity. Credit: 2023 Liu et al.A new editorial paper was published inOncotarget's&nbs

Oncology February 01,2024

Study: Tumor necroptosis promotes metastasis by modulating tumor-host immunity

by Impact Journals LLCTumor necroptosis promotes metastasis of breast cancer by suppressing anti-tumor immunity. Credit: 2023 Liu et al.A new editorial paper was published inOncotarget's&nbs

Oncology February 01,2024

A HER2-targeting peptide drug conjugate with better penetrability for effective breast cancer therapy

by Compuscript LtdSchematic diagram and pharmacokinetics of HER2-TP-cy5.5 and HER-TA-cy5.5 conjugate synthesis. (A) Schematic representation of the utilization of HER2-targeting peptide/antibody and C

Oncology February 01,2024

A HER2-targeting peptide drug conjugate with better penetrability for effective breast cancer therapy

by Compuscript LtdSchematic diagram and pharmacokinetics of HER2-TP-cy5.5 and HER-TA-cy5.5 conjugate synthesis. (A) Schematic representation of the utilization of HER2-targeting peptide/antibody and C

Oncology February 01,2024

Can an annual blood test find cancer while it's curable?

by Lisa M. KriegerCredit: Unsplash/CC0 Public DomainDespite decades of effort in the war against cancer, screening tests are available for only five types of the disease, representing less than one-th

Oncology February 01,2024

Can an annual blood test find cancer while it's curable?

by Lisa M. KriegerCredit: Unsplash/CC0 Public DomainDespite decades of effort in the war against cancer, screening tests are available for only five types of the disease, representing less than one-th

Oncology February 01,2024

Researchers discover how to steer army of immune cells toward cancer

by University of Rochester Medical CenterhHER2 CAR-T cell assays and in vivo distribution. a. Gating strategy for detection of hHER2-CAR-T cells. A median of > 90% of mouse CD8 T cells transdu

Oncology February 01,2024

Researchers discover how to steer army of immune cells toward cancer

by University of Rochester Medical CenterhHER2 CAR-T cell assays and in vivo distribution. a. Gating strategy for detection of hHER2-CAR-T cells. A median of > 90% of mouse CD8 T cells transdu

Oncology February 01,2024

Study identifies molecular basis of resistance to one of the main treatments for multiple myeloma

by The Spanish National Cancer Research CentreCredit: Pixabay/CC0 Public DomainMultiple myeloma is a type of cancer that affects plasma cells, the blood cells involved in the production of antibo

Oncology February 01,2024

Study identifies molecular basis of resistance to one of the main treatments for multiple myeloma

by The Spanish National Cancer Research CentreCredit: Pixabay/CC0 Public DomainMultiple myeloma is a type of cancer that affects plasma cells, the blood cells involved in the production of antibo

Oncology February 01,2024

Drug approved to help young patients battle a rare cancer

by Cara Murez HealthDay ReporterChildren and adults with a rare type of soft tissue cancer will now have a new treatment option that could have a big impact.The U.S. Food and Drug Administration has&n

Oncology February 01,2024

Drug approved to help young patients battle a rare cancer

by Cara Murez HealthDay ReporterChildren and adults with a rare type of soft tissue cancer will now have a new treatment option that could have a big impact.The U.S. Food and Drug Administration has&n

Oncology February 01,2024

Deep in the bile ducts, researchers explore how cancer arises

by Leslie Orr,University of Rochester Medical CenterGraphical abstract. Credit:Cell Reports(2022). DOI: 10.1016/j.celrep.2022.111253A Wilmot Cancer Institute scientist discovered how

Oncology February 01,2024

Deep in the bile ducts, researchers explore how cancer arises

by Leslie Orr,University of Rochester Medical CenterGraphical abstract. Credit:Cell Reports(2022). DOI: 10.1016/j.celrep.2022.111253A Wilmot Cancer Institute scientist discovered how

Oncology February 01,2024

Researchers identify promising new target for drug-resistant breast and ovarian cancers

by Lisa Marshall, University of Colorado at BoulderGraphical abstract. Credit:Molecular Cell(2023). DOI: 10.1016/j.molcel.2023.03.017CU Boulder researchers have discovered a protein's

Oncology February 01,2024

Researchers identify promising new target for drug-resistant breast and ovarian cancers

by Lisa Marshall, University of Colorado at BoulderGraphical abstract. Credit:Molecular Cell(2023). DOI: 10.1016/j.molcel.2023.03.017CU Boulder researchers have discovered a protein's

Oncology February 01,2024